Omnicell, Inc. (NASDAQ:OMCL) Shares Bought by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC lifted its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 27.1% during the third quarter, HoldingsChannel reports. The firm owned 1,140,873 shares of the company’s stock after purchasing an additional 243,353 shares during the quarter. ArrowMark Colorado Holdings LLC’s holdings in Omnicell were worth $49,742,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Verition Fund Management LLC acquired a new position in Omnicell in the 3rd quarter worth $388,000. Rockefeller Capital Management L.P. lifted its stake in shares of Omnicell by 3.7% in the third quarter. Rockefeller Capital Management L.P. now owns 453,708 shares of the company’s stock worth $19,777,000 after acquiring an additional 16,116 shares in the last quarter. Walleye Capital LLC boosted its holdings in Omnicell by 44.0% in the third quarter. Walleye Capital LLC now owns 18,214 shares of the company’s stock valued at $794,000 after purchasing an additional 5,569 shares during the last quarter. Martingale Asset Management L P acquired a new stake in Omnicell during the 3rd quarter valued at approximately $507,000. Finally, PEAK6 Investments LLC purchased a new stake in Omnicell during the 3rd quarter worth approximately $448,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Barclays increased their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Benchmark reissued a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Wells Fargo & Company boosted their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research report on Monday, October 14th. Bank of America reaffirmed a “neutral” rating and set a $57.00 price target (up previously from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Finally, JPMorgan Chase & Co. boosted their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $52.00.

Omnicell Price Performance

Omnicell stock opened at $46.59 on Monday. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.74. The stock has a market capitalization of $2.16 billion, a PE ratio of -119.46, a price-to-earnings-growth ratio of 35.40 and a beta of 0.81. The firm has a 50 day simple moving average of $44.55 and a 200-day simple moving average of $38.05.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.